Duque J L, Loughlin K R
Department of Surgery, Children's Hospital, Boston, Massachusetts.
Urol Clin North Am. 2000 Feb;27(1):125-35, x. doi: 10.1016/s0094-0143(05)70240-8.
Superficial bladder cancer accounts for approximately 70% to 80% of all newly diagnosed bladder cancers. The vast majority of these cancers are transitional bladder tumors of various histologic grades (I to III). Superficial tumors include carcinoma in situ (CIS), tumors confined to the epithelium (Ta), and superficial tumors that invade the lamina propria (T1) but do not involve superficial muscle layers. The primary treatment for eradication of stage Ta and T1 bladder cancers is transurethral resection of the tumor. Many patients with superficial bladder tumors treated with endoscopic surgery alone have recurrence or tumor progression at some point in their follow-up, and, in these patients, the need for adjuvant treatment becomes a major concern.
浅表性膀胱癌约占所有新诊断膀胱癌的70%至80%。这些癌症绝大多数是不同组织学分级(I至III级)的移行性膀胱肿瘤。浅表性肿瘤包括原位癌(CIS)、局限于上皮层的肿瘤(Ta)以及侵犯固有层但未累及浅表肌层的浅表性肿瘤(T1)。根除Ta期和T1期膀胱癌的主要治疗方法是经尿道肿瘤切除术。许多仅接受内镜手术治疗的浅表性膀胱肿瘤患者在随访的某个阶段会出现复发或肿瘤进展,对于这些患者,辅助治疗的必要性成为一个主要问题。